Furthermore, the immune-related genes of CCL19, CXCL5, and UMODL1 might be potential predictors for immunotherapy in the neoadjuvant setting for ESCC, but which still need to be further confirmed. This evidence concerns the gene CCL19 and esophageal squamous cell carcinoma.